Current and emerging pharmacotherapy for prediabetes: are we moving forward?

References

• Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes. 2015;6(2):296–303. 03/15 08/29/received 10/10/revised 12/29/accepted.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes 2017. DiabetesCare. 2017;40(Suppl. 1):S33–S43.
   Google Scholar
• National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk 2012 [2018 feb 28]. Available from: https://www.nice.org.uk/guidance/ph38/chapter/glossary
   Google Scholar
• Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the united states, 1988–2012. JAMA. 2015;314(10):1021–1029.
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Montori VM. The epidemic of pre-diabetes: the medicine and the politics. Bmj. 2014 Jul 15;349:g4485.
   PubMed Web of Science ®Google Scholar
• Tuso P. Prediabetes and lifestyle modification: time to prevent a preventable disease. Perm J. 2014 Summer;18(3): 88–93, PubMed PMID: 25102521; PubMed Central PMCID: PMCPMC4116271. eng.
   PubMedGoogle Scholar
• Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the diabetes prevention program outcomes study. Lancet. 2012 Jun 16;379(9833):2243–2251. PubMed PMID: 22683134; PubMed Central PMCID: PMCPMC3555407. eng.
   PubMed Web of Science ®Google Scholar
• Færch K, Borch-Johnsen K, Holst JJ, et al. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia. 2009;52(9):1714–1723.
   PubMed Web of Science ®Google Scholar
• Tabák AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. The Lancet. 2009;373(9682):2215–2221.
   PubMed Web of Science ®Google Scholar
• Tabák AG, Herder C, Rathmann W, et al. Prediabetes: A high-risk state for developing diabetes. Lancet. 2012 Jun 09;379(9833):2279–2290. PubMed PMID: PMC3891203.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance [10.2337/dc07-9920]. Diabetes Care. 2007;30(3):753.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007 Dec;78(3):305–312. PubMed PMID: 17601626; eng.
   PubMed Web of Science ®Google Scholar
• Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet. 2008 May 24;371(9626):1783–1789. PubMed PMID: 18502303; eng.
   PubMed Web of Science ®Google Scholar
• Gillett M, Royle P, Snaith A, et al. Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technol Assess. 2012 Aug;16(33):1–236, iii-iv. PubMed PMID: 22935084; PubMed Central PMCID: PMCPMC4780928. eng.
   PubMed Web of Science ®Google Scholar
• Hoehner CM, Greenlund KJ, Rith-Najarian S, et al. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. the inter-tribal heart project. J Am Soc Nephrol. 2002 Jun;13(6):1626–1634. PubMed PMID: 12039992; eng.
   PubMed Web of Science ®Google Scholar
• Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010 Apr;5(4):673–682. PubMed PMID: 20338960; PubMed Central PMCID: PMCPMC2849697. eng.
   PubMed Web of Science ®Google Scholar
• Wong TY, Barr EL, Tapp RJ, et al. Retinopathy in persons with impaired glucose metabolism: the Australian diabetes obesity and lifestyle (AusDiab) study. Am J Ophthalmol. 2005 Dec;140(6):1157–1159. PubMed PMID: 16376677; eng.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Programme Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the diabetes prevention program. Diabet Med. 2007 Feb;24(2):137–144. PubMed PMID: 17257275; PubMed Central PMCID: PMCPMC2267935. eng.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Rathmann W, Dickhaus T, et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg surveys S2 and S3. Diabetes Care. 2008 Mar;31(3):464–469. PubMed PMID: 18039804; eng.
   PubMed Web of Science ®Google Scholar
• Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis [10.1136/bmj.i5953]. BMJ. 2016;355.
   PubMedGoogle Scholar
• Karve A, Hayward RA. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults [10.2337/dc09-1957]. Diabetes Care. 2010;33(11):2355.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence Type 2 diabetes: prevention in people at high risk 2012 [ updated Sep 2017 022018 Mar]. Available from: https://www.nice.org.uk/guidance/ph38
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes 2017. J Clin Appl Res Educ. 2017;40(Supplement 1):43–44.
   Google Scholar
• Tseng E, Yeh HC, Maruthur NM. Metformin use in prediabetes among U.S. adults, 2005–2012. Diabetes Care. 2017 Jul;40(7):887–893. PubMed PMID: 28373205; PubMed Central PMCID: PMCPMC5481991. eng.
   PubMed Web of Science ®Google Scholar
• Molitch ME, Fujimoto W, Hamman RF, et al. The diabetes prevention program and its global implications. J Am Soc Nephrol. 2003;14(suppl 2):S103–S107.
   PubMedGoogle Scholar
• Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009 Oct 29;374(9702):1677–1686. PubMed PMID: PMC3135022.
   PubMed Web of Science ®Google Scholar
• Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, et al. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol. 2012. 06/08 03/23/received 05/19/accepted; 11:64-64. PubMed PMID: PMC3434036. DOI:10.1186/1475-2840-11-64
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Snehalatha C, Mary S, et al. The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006 Feb;49(2):289–297. PubMed PMID: 16391903; eng.
   PubMed Web of Science ®Google Scholar
• Iqbal Hydrie MZ, Basit A, Shera AS, et al. Effect of intervention in subjects with high risk of diabetes mellitus in Pakistan. J Nutr Metab. 2012 July 19;2012:867604. 01/25/received 06/05/accepted. PubMed PMID: PMC3409548. .
   PubMedGoogle Scholar
• Pathak R, Bridgeman MB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of Diabetes. Pharm Ther. 2010;35(9): 509–513. PubMed PMID: PMC2957740.
   Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995 Sep;44(9):1126–1131. PubMed PMID: 7657039; eng.
   PubMed Web of Science ®Google Scholar
• Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004 Nov-Dec;36(11–12):761–765. . PubMed PMID: 15655705; eng.
   PubMed Web of Science ®Google Scholar
• Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002 Feb;45(2):195–202. PubMed PMID: 11935150.
   PubMed Web of Science ®Google Scholar
• Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2007 Feb;16(2):231–237. . PubMed PMID: 17243943.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007 Jun;30(6):1608–1610. PubMed PMID: 17372153.
   PubMed Web of Science ®Google Scholar
• Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606–1616. PubMed PMID: 19853906; eng.
   PubMed Web of Science ®Google Scholar
• Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36(6):843–854. 06//print: http://www.nature.com/ijo/journal/v36/n6/suppinfo/ijo2011158s1.html
   PubMed Web of Science ®Google Scholar
• Kim SH, Abbasi F, Lamendola C, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013 Oct;36(10):3276–3282. PubMed PMID: 23835684; PubMed Central PMCID: PMCPMC3781545. eng.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England J Med. 2015 2015 Jul 02; 373(1):11–22.
   PubMed Web of Science ®Google Scholar
• le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017 Apr 08;389(10077):1399–1409. PubMed PMID: 28237263; eng.
   PubMed Web of Science ®Google Scholar
• Unger JR, Parkin CG. Glucagon-like peptide-1 (GLP-1) receptor agonists: differentiating the new medications. Diabetes Therapy. 2011;2(1):29–39. 01/1811/11/received.
   PubMedGoogle Scholar
• Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33(6):1173–1175. 03/23 07/01/received03/08/accepted.
   PubMed Web of Science ®Google Scholar
• Kaku K, Kadowaki T, Terauchi Y, et al. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes Obes Metab. 2015;17(11):1033–1041. 07/17 01/25/received05/31/revised06/06/accepted.
   PubMed Web of Science ®Google Scholar
• Hage C, Brismar K, Efendic S, et al. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities–the BEGAMI study. J Intern Med. 2013 Apr;273(4):410–421. PubMed PMID: 23331339; eng.
   PubMed Web of Science ®Google Scholar
• Naidoo P, Wing J, Rambiritch V. Effect of sitagliptin and metformin on prediabetes progression to type 2 diabetes - a randomized, double-blind, double-arm, multicenter clinical trial: protocol for the sitagliptin and metformin in prediabetes (SiMePreD) study. JMIR Res Protoc. 2016;5(3):e145. Jul-Sep08/04 08/26/received 01/05/rev-request 01/23/revised 01/24/accepted.
   PubMed Web of Science ®Google Scholar
• DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet. 1096–1105;368(9541). DOI:10.1016/S0140-6736(06)69420-8
   Web of Science ®Google Scholar
• Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010 Jul 10;376(9735):103–111. PubMed PMID: 20605202; eng.
   PubMed Web of Science ®Google Scholar
• Chiasson J-L, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The Lancet. 2002;359(9323):2072–2077.
   PubMed Web of Science ®Google Scholar
• Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009 May 9;373(9675):1607–1614. PubMed PMID: 19395079; eng.
   PubMed Web of Science ®Google Scholar
• Díaz-Redondo A, Giráldez-García C, Carrillo L, et al. Modifiable risk factors associated with prediabetes in men and women: a cross-sectional analysis of the cohort study in primary health care on the evolution of patients with prediabetes (PREDAPS-Study). BMC Fam Pract. 2015;16:5. 01/22 10/27/received 12/16/accepted. PubMed PMID: PMC4316391.
   PubMed Web of Science ®Google Scholar
• Wang H, Shara NM, Calhoun D, et al. Incidence rates and predictors of diabetes in those with prediabetes: the strong heart study. Diabetes Metab Res Rev. 2010 Jul;26(5):378–385. PubMed PMID: 20578203; PubMed Central PMCID: PMCPMC2897954. eng.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012;59(7):635–643.
   PubMed Web of Science ®Google Scholar
• Hertzman P. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden: a treatment responder approach. Pharmacoeconomics. 2005;23(10): 1007–1020. PubMed PMID: 16235974; eng.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Crombie A, Sanders LF, et al. Efficacy of orlistat 60 mg on weight loss and body fat mass in US army soldiers. J Acad Nutr Diet. 2012 Apr;112(4):533–540. PubMed PMID: 22717217; eng.
   PubMed Web of Science ®Google Scholar
• Chanoine JP, Richard M. Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. Int J Pediatr Obes. 2011 Apr;6(2):95–101. . PubMed PMID: 20858149; eng.
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000 May 8;160(9):1321–1326. PubMed PMID: 10809036; eng.
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese Subjects (XENDOS) study [10.2337/diacare.27.1.155]. Diabetes Care. 2004;27(1):155.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone sr/bupropion sr on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring, Md). 2013;21(5):935–943. 02/14 10/16/received 12/04/accepted.
   PubMed Web of Science ®Google Scholar
• Amy E, Ks H, Hollander P. Prolonged-Release Naltrexone/Bupropion Improves Glucose Control in Individuals with Prediabetes. 2017.
   Google Scholar
• de la Cruz-Muñoz N, Messiah SE, Arheart KL, et al. Bariatric surgery significantly decreases the prevalence of type 2 diabetes mellitus and pre-diabetes among morbidly obese multiethnic adults: long-term results. J Am Coll Surg. 2011;212(4):505–511.
   PubMed Web of Science ®Google Scholar
• Carlsson LMS, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in swedish obese subjects. New England J Med. 2012;367(8):695–704.
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Buse JB, Tuomilehto J, et al. Update and next steps for real-world translation of interventions for type 2 diabetes prevention: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2016 Jun 09;39(7):1186–1201. PubMed PMID: PMC4915559.
   PubMed Web of Science ®Google Scholar